Xencor Inc (XNCR) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
XNCR currently has 75.2M outstanding shares. with minimal authorized share overhang for future dilution. The company has diluted shareholders by 20.79% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 06, 2026 |
10-Q filing | 75.2M shares outstanding |
75M | 0 |
| Nov 05, 2025 |
10-Q filing | 74.4M shares outstanding |
74M | 0 |
| Aug 06, 2025 |
10-Q filing | 74.3M shares outstanding |
74M | 0 |
| May 07, 2025 |
10-Q filing | 73.7M shares outstanding |
74M | 0 |
| Feb 27, 2025 |
10-K filing | 65.0M shares outstanding |
65M | 0 |
| Nov 06, 2024 |
10-Q filing | 64.0M shares outstanding |
64M | 0 |
| Sep 12, 2024 |
8-K filing: Xencor, Inc. announced the closing of its underwritten public offering of common stock, selling 8,093,712 shares at $18.00 per share and pre-funded warrants to purchase 3,088,888 shares at $17.99 per share. |
62M | 0 |
| Sep 12, 2024 |
8-K filing: Xencor, Inc. entered into an underwriting agreement for a public offering of 6,635,112 shares of common stock and pre-funded warrants to purchase up to 3,088,888 shares of common stock at a public offering price of $18.00 per share of common stock and $17.99 per pre-funded warrant, with gross proceeds of approximately $175 million. ($175.0M proceeds) |
62M | 0 |
| Aug 05, 2024 |
10-Q filing | 61.7M shares outstanding |
62M | 0 |
| May 09, 2024 |
10-Q filing | 61.2M shares outstanding |
61M | 0 |
| Feb 29, 2024 |
10-K filing | 60.5M shares outstanding |
61M | 0 |
| Nov 08, 2023 |
10-Q filing | 60.6M shares outstanding |
61M | 0 |
| Aug 03, 2023 |
10-Q filing | 59.8M shares outstanding |
60M | 0 |
| May 08, 2023 |
10-Q filing | 59.8M shares outstanding |
60M | 0 |
| Feb 27, 2023 |
10-K filing | 59.7M shares outstanding |
60M | 0 |
| Nov 07, 2022 |
10-Q filing | 59.7M shares outstanding |
60M | 0 |
| Aug 03, 2022 |
10-Q filing | 59.6M shares outstanding |
60M | 0 |
| May 05, 2022 |
10-Q filing | 59.4M shares outstanding |
59M | 0 |
| Feb 24, 2022 |
10-K filing | 58.4M shares outstanding |
58M | 0 |
| Nov 08, 2021 |
10-Q filing | 58.4M shares outstanding |
58M | 0 |
| Oct 04, 2021 |
8-K filing: Xencor entered into a Collaboration and License Agreement with Janssen Biotech, Inc. where Johnson & Johnson Innovation-JJDC, Inc., will purchase $25 million of newly issued unregistered shares of Xencor common stock, priced at a 30-day volume-weighted average price of $33.4197 per share, totaling 748,062 shares. ($25.0M proceeds) |
58M | 0 |
| Aug 04, 2021 |
10-Q filing | 58.2M shares outstanding |
58M | 0 |
| May 05, 2021 |
10-Q filing | 58.2M shares outstanding |
58M | 0 |
| Feb 24, 2021 |
10-K filing | 57.2M shares outstanding |
57M | 0 |
| Nov 06, 2020 |
10-Q filing | 57.3M shares outstanding |
57M | 0 |
| Aug 05, 2020 |
10-Q filing | 57.1M shares outstanding |
57M | 0 |
| May 08, 2020 |
10-Q filing | 56.9M shares outstanding |
57M | 0 |
| Feb 25, 2020 |
10-K filing | 56.5M shares outstanding |
57M | 0 |